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Abstract: Vitamin D has been suggested to play a role in glucose metabolism. However, previous
findings are contradictory and mechanistic pathways remain unclear. We examined the relationship
between plasma 25-hydroxyvitamin D (25(OH)D), insulin sensitivity, and insulin signaling in
skeletal muscle and adipose tissue. Seventeen healthy adults (Body mass index: 26 ± 4; Age:
30 ± 12 years) underwent a hyperinsulinemic-euglycemic clamp, and resting skeletal muscle and
adipose tissue biopsies. In this cohort, the plasma 25(OH)D concentration was not associated with
insulin sensitivity (r = 0.19, p = 0.56). However, higher plasma 25(OH)D concentrations correlated
with lower phosphorylation of glycogen synthase kinase-3 (GSK-3) αSer21 and βSer9 in skeletal
muscle (r = −0.66, p = 0.015 and r = −0.53, p = 0.06, respectively) and higher GSK-3 αSer21 and βSer9
phosphorylation in adipose tissue (r = 0.82, p < 0.01 and r = 0.62, p = 0.042, respectively). Furthermore,
higher plasma 25(OH)D concentrations were associated with greater phosphorylation of both protein
kinase-B (AktSer473) (r = 0.78, p < 0.001) and insulin receptor substrate-1 (IRS-1Ser312) (r = 0.71, p = 0.01)
in adipose tissue. No associations were found between plasma 25(OH)D concentration and IRS-1Tyr612
phosphorylation in skeletal muscle and adipose tissue. The divergent findings between muscle and
adipose tissue with regard to the association between 25(OH)D and insulin signaling proteins may
suggest a tissue-specific interaction with varying effects on glucose homeostasis. Further research is
required to elucidate the physiological relevance of 25(OH)D in each tissue.
Keywords: diabetes; glucose homeostasis; insulin resistance; insulin signaling; vitamin D;
25-hydroxyvitamin D
1. Introduction
Vitamin D, in its hydroxylated form, 25-hydroxyvitamin D (25(OH)D), and its biologically active
form, 1,25-dihydroxyvitamin D (1,25(OH)2D), is an important regulator of calcium, phosphorus, and
bone metabolism [1]. Vitamin D is primarily produced in the skin in response to ultraviolet B radiation
but can also be obtained from diet (e.g., high-fat fish, liver, or fortified milk) or supplementation
in the form of vitamin D2 or D3 [2,3]. Vitamin D is transported to the liver in blood via vitamin D
binding proteins where it is hydroxylated to form 25(OH)D, the most abundant circulating form
of vitamin D. 25(OH)D is then transported to the kidney and hydroxylated to the hormonally
active form of 1,25(OH)2D which is suggested to elicit many, if not all, of the biological actions
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of vitamin D [4]. Vitamin D status is primarily measured via serum/plasma 25(OH)D due to the
substantially greater half-life and abundance in serum/plasma compared to 1,25(OH)2D and the
absence of confounding factors such as elevated 1,25(OH)2D concentrations in vitamin D-insufficient
and -deficient populations [5]. Although variations permeate the literature, vitamin D status is
generally considered to be deficient when 25(OH)D serum concentrations are <25 nmol/L, insufficient
when between 25 and 49 nmol/L, and sufficient when ≥50 nmol/L [6]. Vitamin D deficiency is linked
to the development of several pathologies including cancer, autoimmune diseases, infectious diseases,
and inflammatory conditions [7]. In addition, previous reports suggest that vitamin D plays a role in
glycemic control [8,9] which can be improved through vitamin D supplementation [8–10]; however,
findings are contradictory [11–13]. Potential cellular pathways are unclear, but may occur through
direct binding of vitamin D to vitamin D receptors and activation of downstream signaling proteins;
through increased gene expression of the insulin receptor; and indirectly through calcium regulation
and subsequent downstream effects on glucose homeostasis signaling proteins [14–17]. Previous
reports indicate that vitamin D supplementation in high-fat diet–fed mice attenuates weight gain
and increases transcriptional activity of the insulin receptor substrate-1 (IRS-1) in skeletal muscle
but not adipose tissue [18]. Likewise, 1,25(OH)2D treatment in C2C12 cells rescues diet-induced
insulin resistance via decreased IRS-1 serine phosphorylation and increased IRS-1 tyrosine and protein
kinase-B (Akt) serine phosphorylation [19]. Further, 1,25(OH)2D also participates in skeletal muscle
cell proliferation and differentiation through a phosphoinositide 3-kinase/Akt-dependent signaling
pathway [20] that is known to regulate glycemic control [21]. However, to the best of our knowledge,
there is no human data on insulin signaling. Therefore, the aim of this study was to test the hypothesis
that vitamin D status and 25(OH)D in humans is related to insulin signaling proteins in both skeletal
muscle and adipose tissue.
2. Materials and Methods
This study is a subset of a larger study of 111 healthy normoglycemic adults, where we reported
a positive association between plasma 25(OH)D concentration and insulin sensitivity measured
by hyperinsulinemic-euglycemic clamp [22]. Due to the invasive nature of skeletal muscle and
subcutaneous adipose tissue sampling in humans, the sample size is limited to seventeen adults
(ten males and seven females) who had participated in the larger study. Detailed methodology for
medical pre-screening, insulin sensitivity and protein analysis have previously been reported [22].
In brief, biopsies of subcutaneous adipose and vastus lateralis muscle were performed at rest prior to
the hyperinsulinemic-euglycemic clamp after a 12 h overnight fast, under local anesthesia, and using
standard aseptic techniques. Following a 7 mm skin incision to cut the fascia prior to the muscle
biopsy, a side-cutting muscle biopsy needle was passed through to obtain ~100 mg of muscle tissue.
Using a 50 mL plastic syringe attached to a 13 gauge aspiration needle, adipose tissue was obtained
from the abdominal area, 1–2 cm superior to McBurney’s point. Both muscle and adipose tissues were
immediately placed in liquid nitrogen and then stored at 80 ◦C.
Insulin sensitivity was measured via a 2 h hyperinsulinemic-euglycemic clamp. Insulin was
infused at a constant rate of 40 mU/m2/min and the glucose infusion rate (GIR) was averaged over the
last 40 min of the insulin clamp and expressed relative to serum insulin levels (m-value; mg/kg/min).
Fasting blood samples for 25(OH)D analysis were drawn prior to the start of the insulin clamp. Primary
antibodies specific for phosphorylation of glycogen synthase kinase (GSK-3) α/βSer21/9 (Cell Signaling
Technology, Danvers, MA, USA), protein kinase-B (AktSer473; Cell Signaling Technology, Danvers,
MA, USA), serine phosphorylation of human insulin receptor substrate 1 (IRS-1Ser312; Biosource),
and tyrosine phosphorylation of IRS-1Tyr612 (Biosource), were used to quantify muscle and adipose
tissue protein as per methods previously reported [23].
Vitamin D assays were performed using a DiaSorin Liaison Analyser (DiaSorin Inc., Stillwater,
MN, USA), which uses the direct competitive chemiluminescent immunoassay method (CLIA) to
quantitatively determine the total 25(OH)D in plasma. During the first incubation, 25(OH)D is
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dissociated from its binding proteins and binds to the specific antibody on the solid phase. After 10 min,
the tracer (vitamin D linked to an isoluminol derivative) is added. Following a second incubation,
the unbound material is removed with a wash cycle and the starter reagent is added to initiate
a flash chemiluminescent reaction. The light signal emitted is measured by a photomultiplier as
relative light units (RLU) and is inversely proportional to the concentration of 25(OH)D present in the
sample. Inter- and intra-assay coefficients of variation (CV) using the Diasorin method were <10% and
<4%, respectively.
All data were log transformed to approximate normal distribution prior to analysis. Unpaired
t-tests assuming equal variance were conducted to compare mean insulin sensitivity values between
groups of different vitamin D status. Correlations of combined data, and data stratified by
deficient/insufficient (25(OH)D < 50 nmol/L) and sufficient (25(OH)D ≥ 50 nmol/L) vitamin D
status, were analyzed using linear regression analysis. Due to difficulty in adipose tissue and skeletal
muscle sampling in humans, samples were not available for some protein analysis for all subjects
(n = 11–16). Cook’s Distance was used as a measure of influence where observations greater than 4/N
Cook’s D were excluded from correlation analysis [24]. All data are reported as mean ± SD and all
statistical analyses were conducted at the 95% level of significance (p < 0.05).
Ethical approval was obtained from the Alfred Hospital Ethics Committee and the Monash
University Human Research Ethics Committee and complied with the Declaration of Helsinki
(2013) [25] All participants provided written informed consent prior to participation. (The ethical
approval code is HREC 131/04).
3. Results
Participant characteristics are reported in Table 1.
Table 1. Participant characteristics.
Variable All Males Females
Age (years) 30 ± 12 (18–49) 28 ± 10 (18–46) 33 ± 13 (21–49)
Height (cm) 172 ± 6 (173–199) 175 ± 5 (167–185) 167 ± 6 (159–176)
Weight (kg) 78 ± 11 (53–99) 81 ± 10 (66–99) 72 ± 12 (53–91)
BMI (kg·m−2) 26 ± 4 (21–34) 27 ± 4 (22–34) 26 ± 4 (21–31)
Plasma 25(OH)D (nmol/L) 57 ± 31 (22–138) 65 ± 35 (23–138) 47 ± 20 (22–78)
Vitamin D status (25(OH)D)
Deficient: <25 nmol/L 3 1 2
Insufficient: 25–49 nmol/L 6 4 2
Sufficient: ≥50 nmol/L 8 5 3
GIR per unit of insulin (M-value; mg/kg/min) 10 ± 5 (3–17) 9 ± 3 (4–15) 10 ± 6 (3–17)
Data presented as mean ± SD (Range); BMI, body mass index; 25(OH)D, 25-hydroxyvitamin D, GIR, glucose
infusion rate.
3.1. Plasma 25(OH)D and Insulin Sensitivity
As previously reported, in the larger sample of 111 individuals (66 males, 45 females,
age = 31.1 ± 9.2 years, body mass index (BMI) = 30.2 ± 5.1 kg/m2), there was a positive association
between 25(OH)D and insulin sensitivity (r = 0.20, p = 0.04). In the subgroup of 17 individuals
where skeletal muscle and adipose tissue was available, the M-value was not significantly different
between vitamin D–deficient/–insufficient (30± 10 nmol/L) and vitamin D-sufficient (82± 28 nmol/L)
individuals (p = 0.9; Figure 1). The plasma 25(OH)D concentration was not associated with insulin
sensitivity (M-value) (r = 0.10, p = 0.69), even after adjustment for age, BMI, fat mass, sex, and vitamin D
status (r = 0.19, p = 0.56).
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Figure 1. Insulin sensitivity (M-value; A), as measured by hyperinsulinemic-euglycemic clamp,
stratified by deficient/insufficient and replete vitamin D status.
3.2. Plasma 25(OH)D and Protein Regulators of Insulin Signaling
In skeletal muscle, a higher plasma 25(OH)D concentration was associated with lower
phosphorylation of GSK-3 αSer21 and βSer9, but the latter did not reach significance (p = 0.06), whereas
in adipose tissue 25(OH)D was associated with a higher phosphorylation of GSK-3 αSer21 and βSer9
(Figure 2). In adipose tissue, a higher plasma 25(OH)D concentration was associated with greater
phosphorylation of AktSer473 and IRS-1Ser312 (Figure 2), whereas these associations were not detected
in skeletal muscle (p = 0.99 and p = 0.56, respectively; data not shown). Tyrosine phosphorylation
of IRS-1Tyr612 in adipose tissue and skeletal muscle did not correlate with 25(OH)D concentrations
(p = 0.95 and p = 0.3, respectively; data not shown). GSK-3 αSer21 and βSer9 phosphorylation was
associated with higher phosphorylat d AktSer473 in adipose tissue (Figure 3) but not in skeletal muscle
(p = 0.93 and p = 0.6, respectively; data not shown).
Insulin sensitivity was not associated with phosphorylation of GSK-3 αSer21 and βSer9 in skeletal
muscle (p = 0.83 and p = 0.92, respectively; data not shown) or adipose tissue (p = 0.28 and p = 0.42,
respectively; data not shown). On the other hand, insulin sensitivity was associated with higher
phosphorylation of AktSer473 and lower phosphorylation of IRS-1Ser312 in skeletal muscle (Figure 4),
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adipose  tissue  and  skeletal muscle:  (A) Plasma  25(OH)D  and phosphorylation  of GSK‐3  αSer21  in 
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Figure 2. Linear regression between plasma vitamin D (25(OH)D) and insulin signaling proteins
in adipose tissue and skeletal muscle: (A) Plasma 25(OH)D and phosphorylation of GSK-3 αSer21
in skeletal muscle; (B) Plasma 25(OH)D and phosphorylation of GSK-3 βSer9 in skeletal muscle;
(C) Plasma 25(OH)D and phosphorylation of GSK-3 αSer21 in adipose tissue; (D) Plasma 25(OH)D
and phosphorylation of GSK-3 βSer9 in adipose tissue; (E) Plasma 25(OH)D and phosphorylation of
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Figure 3. Linear regression between: (A) Phosphorylated AktSer473 and phosphorylation of GSK-3
αSer21 in adipose tissue; (B) Phosphorylated AktSer473 and GSK-3 βSer9 in adipose tissue.
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women has been reported to reduce insulin resistance when endpoint 25(OH)D concentrations were 
equal  to  or  exceeded  80  nmol/L  [27],  suggesting  that  a  potentially  higher  physiological  limit  of 
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An  important  finding  of  the  current  study was  the  strong  correlation  between  the  plasma 
25(OH)D concentration and key insulin signaling proteins involved in glucose homeostasis, which 
appear to occur in a tissue‐specific manner. Previous reports suggest that vitamin D deficiency may 
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Figure 4. Linear regression between: (A) Insulin sensitivity (M-value) and AktSer473 phosphorylation
in skeletal muscle; (B) Insulin sensitivity (M-value) and IRS-1Ser312 phosphorylation in skeletal muscle.
4. Discussion
We r port that the association betwe n 25(OH)D and ins li si li r teins appears to be
tissue specifi . Differential associations were detect d between 25(OH)D concentration and key glucose
homeostasis signaling prote s IRS-1Ser312, GSK-3 α/βSer21/9, and AktSer473, in uscle and
adipose tissue.
Considering the well-known role of c l lyce ic control [16] and given that vitamin D
is calcitropic hormone, it was hypothesized that vita in D may ls play a role in glucose
metabolism [8–10]. We previously reported that plasma 25(OH)D was related to insulin se sitivity in
a larger study [22]; however, this relationship was not present in the subgroup analysis of participants
who underwent skeletal muscle and adipose tissue sampling. Similar to our findings, previous
studies using the hyperinsulinemic-euglycemic clamp with similar sample sizes have reported that
vitamin D supplementation in both vitamin D-deficient/-insufficient [13] and replete individuals [26]
has a modest effect on insulin sensitivity. In contrast, vitamin D supplementation in insulin-resistant
women has been reported to reduce insulin resistance when endpoint 25(OH)D concentrations were
equal to or exceeded 80 nmol/L [27], suggesting that a potentially higher physiological limit of
25(OH)D is required to influence glycemic control. In the current study, no supplementation was
used, only one participant exhibited a plasma 25(OH)D concentration above 80 nmol/L, and a small
sample size may have contributed towards the lack of significant findings which have previously
been reported in epidemiological studies [9,10]. Nevertheless, our findings are in accordance with
intervention studies which have reported that improving vitamin D status plays a limited role in
glucose metabolism [11,13,26,28–33].
An important finding of the current study was the strong correlation between the plasma 25(OH)D
concentration and key insulin signaling proteins involved in glucose homeostasis, which appear to
occur in a tissue-specific manner. Previous reports suggest that vitamin D deficiency may influence
glucose homeost sis through increased intracellular calcium leading to aberrant insulin signaling and
attenuation of downstr am insulin signaling enzymes such as glycogen synthase and the glucose
transporter 4 (GLUT 4) [8,15,17,34,35]. We repo t the novel finding that higher plasma 25(OH)D
concentr tions were assoc ate with greater serine phosphorylation of GSK-3 α/β and its upstre m
regulator Akt in adipose tissue, and lowe serine phosphorylation of GSK-3 α/β in skeletal muscle.
GSK-3 is highly active under resting condition in the absence of ins lin and inhibits glycog n
synt ase activity, glycogen synthesis and subsequent glucose uptake, via serine phosphorylation
on residues 21 and 9 [36,37]. The association of higher plasma 25(OH)D with lower GSK-3 serine
phosphorylation in skeletal muscle suggests greater basal inhibition of glycogen synthase activity,
glycogen synthesis, and glucose uptake, whereas higher GSK-3 serine phosphorylation in adipose
tissue suggests upregulation of this pathway. This inverse relationship between 25(OH)D and serine
phosphorylated GSK-3 α/β in muscle and adipose tissue may indicate a tissue-specific role for
25(OH)D in GSK-3 function. Previous reports indicate that higher protein expression of GSK-3 (often
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elevated in patients with type 2 diabetes) is related to lower insulin action in skeletal muscle, whereas
GSK-3 in adipose tissue is less likely to play a role in whole body glucose disposal [38]. It is also
possible that 25(OH)D may be involved in other GSK-3–mediated cellular processes independent of
glucose regulation, such as gene transcription, mRNA translation, cytoskeletal regulation, cell cycle
progression, and apoptosis [39]. Further research is required to investigate the potential role of
vitamin D status and GSK-3 function in human skeletal muscle and adipose tissue.
Increased phosphorylation of IRS-1Ser312 is implicated with impaired insulin signaling and glucose
uptake in part through IRS-1 degradation, impaired IRS-1 tyrosine phosphorylation, and attenuation
of insulin-stimulated glucose uptake [40]. We report that a higher plasma 25(OH)D concentration
was associated with greater phosphorylation of IRS-1Ser312 in adipose tissue but not in skeletal muscle
tissue. In addition, 25(OH)D concentration was not associated with basal tyrosine phosphorylation of
IRS-1Tyr612, a positive regulator of insulin-stimulated glucose uptake [41], in either tissue. Our findings
contradict previous reports which have reported a role for 1,25(OH)2D in the enhancement of insulin
signaling and insulin sensitivity in non-human studies [18,19], although the measurement of 25(OH)D
and basal insulin signaling in the current study limits comparisons. Prada, Zecchin [42] reported that
IRS-1Ser312 phosphorylation in skeletal muscle likely plays a greater role in insulin sensitivity than
in adipose tissue. Indeed, we report that greater phosphorylation of IRS-1Ser312 in skeletal muscle
only was related to lower whole body insulin sensitivity. Thus, in the context of the current findings,
the plasma 25(OH)D concentration does not appear to be related to basal IRS-1Tyr612 phosphorylation
or IRS-1Ser312 phosphorylation in skeletal muscle; however, future research is required to elucidate the
physiological relevance of 25(OH)D and IRS-1Ser312 signaling in adipose tissue.
This study has potential limitations which include a relatively small sample size, and the
measurement of insulin signaling proteins under basal fasted conditions and not during or after insulin
stimulation. The inclusion of populations who are insulin resistant, have type 2 diabetes, and/or exhibit
a greater range of vitamin D status would allow for greater exploration of the relationship between
vitamin D status, and insulin sensitivity and protein signaling. Future studies are required to confirm
these findings with larger and more diverse populations. Interventional studies in vitamin D–deficient
and insulin-resistant individuals would allow for greater exploration of the physiological role and
relevance of 25(OH)D and insulin signaling proteins. It is possible that vitamin D status is subsidiary
to insulin resistance and an expression of ill health rather than a primary moderator of glycemic
control [43]. However, current evidence is equivocal and further high-quality randomized controlled
trials are required [9].
5. Conclusions
In conclusion, plasma 25(OH)D was strongly associated with phosphorylation of insulin signaling
proteins in a tissue-specific manner. The clinical implications of these findings need to be examined
with adequately powered randomized controlled trials.
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